HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

GYKI 53655

an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist
Also Known As:
1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine; GYKI-53655; LY 300168
Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ko, Shanelle W: 1 article (09/2005)
2. Wu, Long-Jun: 1 article (09/2005)
3. Zhuo, Min: 1 article (09/2005)
4. Zhao, Ming-Gao: 1 article (09/2005)
5. Toyoda, Hiroki: 1 article (09/2005)
6. Ali, Afia B: 1 article (06/2003)
7. Kleinrok, Z: 1 article (11/2001)
8. Urbanska, E M: 1 article (11/2001)
9. Luchowska, E: 1 article (11/2001)
10. Luchowski, P: 1 article (11/2001)

Related Diseases

1. Seizures (Seizure)
06/01/2001 - "In audiogenic seizure model the duration of anticonvulsant action of 10 mg/kg GYKI 52466 and 5 mg/kg GYKI 53405, GYKI 53655 were examined, too. "
08/15/1995 - "1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride (GYKI 52466), up to 5 mg/kg, did not influence the electroconvulsive threshold but potentiated the anticonvulsant activity of valproate, carbamazepine and diphenylhydantoin against maximal electroshock-induced convulsions in mice. "
11/16/2001 - "In this study, we evaluated whether beta-adrenoceptor antagonists may modify the protective efficacy of dizocilpine (MK-801), a NMDA receptor antagonist, and 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466), a non-NMDA (AMPA/kainate) receptor antagonist, against maximal electroshock-induced seizures in mice. "
04/16/1999 - "The occurrence of 3-nitropropionic acid-induced seizures was inhibited by the alpha-amino-2,3-dihydro-5-methyl-3-oxo-isoxazole-propionate (AMPA)/kainate receptor antagonists, 6-nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione disodium (NBQX) and 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine HCI (GYKI 52466), with ED50 of 14.1 (7.9-25.2) and 7.2 (5.3-9.6) mg/kg, respectively. "
06/01/2001 - "GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine], a non-competitive AMPA [alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate] and kainate receptor antagonist and its two analogues, GYKI 53405 [1-(4-aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine] and GYKI 53655 [1-(4-aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine] were investigated in two seizure models and in MgCl2 induced global cerebral ischaemia, as an acute neuroprotective model. "
2. Shock

Related Drugs and Biologics

1. GYKI 52466
2. alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
3. Kainic Acid Receptors (Kainate Receptor)
4. Dizocilpine Maleate (Dizocilpine)
5. N-Methylaspartate (NMDA)
6. AMPA Receptors (AMPA Receptor)
7. Magnesium Chloride
8. Valproic Acid (Valproate, Semisodium)
9. Picrotoxin
10. Phenytoin (Dilantin)